↓ Skip to main content

Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline

Overview of attention for article published in Practical Radiation Oncology, July 2016
Altmetric Badge
44

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#21 of 405)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
65 tweeters
facebook
10 Facebook pages

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
94 Mendeley
Title
Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
Published in
Practical Radiation Oncology, July 2016
DOI 10.1016/j.prro.2016.03.007
Pubmed ID
Authors

Alvin R. Cabrera, John P. Kirkpatrick, John B. Fiveash, Helen A. Shih, Eugene J. Koay, Stephen Lutz, Joshua Petit, Samuel T. Chao, Paul D. Brown, Michael Vogelbaum, David A. Reardon, Arnab Chakravarti, Patrick Y. Wen, Eric Chang

Abstract

To present evidence-based guidelines for radiation therapy in treating glioblastoma not arising from the brainstem. The American Society for Radiation Oncology (ASTRO) convened the Glioblastoma Guideline Panel to perform a systematic literature review investigating the following: (1) Is radiation therapy indicated after biopsy/resection of glioblastoma and how does systemic therapy modify its effects? (2) What is the optimal dose-fractionation schedule for external beam radiation therapy after biopsy/resection of glioblastoma and how might treatment vary based on pretreatment characteristics such as age or performance status? (3) What are ideal target volumes for curative-intent external beam radiation therapy of glioblastoma? (4) What is the role of reirradiation among glioblastoma patients whose disease recurs following completion of standard first-line therapy? Guideline recommendations were created using predefined consensus-building methodology supported by ASTRO-approved tools for grading evidence quality and recommendation strength. Following biopsy or resection, glioblastoma patients with reasonable performance status up to 70 years of age should receive conventionally fractionated radiation therapy (eg, 60 Gy in 2-Gy fractions) with concurrent and adjuvant temozolomide. Routine addition of bevacizumab to this regimen is not recommended. Elderly patients (≥70 years of age) with reasonable performance status should receive hypofractionated radiation therapy (eg, 40 Gy in 2.66-Gy fractions); preliminary evidence may support adding concurrent and adjuvant temozolomide to this regimen. Partial brain irradiation is the standard paradigm for radiation delivery. A variety of acceptable strategies exist for target volume definition, generally involving 2 phases (primary and boost volumes) or 1 phase (single volume). For recurrent glioblastoma, focal reirradiation can be considered in younger patients with good performance status. Radiation therapy occupies an integral role in treating glioblastoma. Whether and how radiation therapy should be applied depends on characteristics specific to tumor and patient, including age and performance status.

Twitter Demographics

The data shown below were collected from the profiles of 65 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 2 2%
Netherlands 1 1%
Unknown 91 97%

Demographic breakdown

Readers by professional status Count As %
Unspecified 14 15%
Researcher 14 15%
Student > Ph. D. Student 13 14%
Other 12 13%
Student > Postgraduate 10 11%
Other 30 32%
Unknown 1 1%
Readers by discipline Count As %
Medicine and Dentistry 54 57%
Unspecified 20 21%
Agricultural and Biological Sciences 4 4%
Biochemistry, Genetics and Molecular Biology 3 3%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 9 10%
Unknown 1 1%

Attention Score in Context

This research output has an Altmetric Attention Score of 44. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2017.
All research outputs
#354,418
of 12,871,560 outputs
Outputs from Practical Radiation Oncology
#21
of 405 outputs
Outputs of similar age
#12,652
of 262,862 outputs
Outputs of similar age from Practical Radiation Oncology
#2
of 17 outputs
Altmetric has tracked 12,871,560 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 405 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,862 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.